Artelo Biosciences Inc. has entered into a definitive agreement with R.F. Lafferty & Co., Inc. to establish an at-the-market equity program. This program allows Artelo to sell up to $6.5 million worth of its common stock through the Manager as needed. The agreement permits sales directly on The Nasdaq Capital Market or other trading platforms, with a commission rate of 2.0% of the gross sales price per share for the Manager. Artelo retains the discretion to set minimum sale prices and can suspend the offering if necessary. The agreement includes standard representations, warranties, and indemnification obligations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-25-001240), on July 18, 2025, and is solely responsible for the information contained therein.